Prostate cancer prognosis in men with other malignancies prior to radical prostatectomy.

All-cause mortality Cancer-specific mortality Competing risk Multiple primary neoplasms Prostate cancer Radical prostatectomy

Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
09 2019
Historique:
received: 23 01 2019
revised: 08 03 2019
accepted: 09 04 2019
pubmed: 3 5 2019
medline: 12 9 2020
entrez: 4 5 2019
Statut: ppublish

Résumé

Cancer survivors are often diagnosed with subsequent prostate cancer. To improve medical care of these patients, we examined the oncological outcomes in men with prostate cancer and a cancer history. We retrospectively analyzed data from 25,422 prostate cancer patients, who underwent a radical prostatectomy between 1992 and 2016. Patients with other malignancies were identified using medical records and self-administrated questionnaires. Cox regression and Kaplan Meier analysis of a propensity score-matched patient cohort were performed to examine biochemical recurrence-free survival, metastasis-free survival, overall survival and prostate cancer-specific survival. Competing risk analysis was used to estimate other-cause mortality, other cancer-specific mortality, and prostate cancer-specific mortality. Statistical analysis was performed using R. Of all patients, 6.4% were diagnosed with other malignancy prior to radical prostatectomy. Patients with tumor history were older (median: 66 years vs. 64 years., P< 0,001) and showed a higher tumor volume (median: 4.0 ml vs. 3.6 ml, P = 0.02) than patients without. The risk of biochemical recurrence and metastasis development after radical prostatectomy was similar. All-cause mortality was significantly increased (hazard ratio 2.0; 95% confidence interval 1.7-2.4), while prostate cancer-specific mortality was lower (hazard ratio 0.4; 95% confidence interval 0.23-0.87) in patients with additional malignancy. In a propensity score-matched cohort overall survival was significantly adverse (P< 0.001) and prostate cancer-specific survival was higher (P= 0.003) in patients with other malignancy prior to surgery. A higher other-cause mortality in men with tumor history should be concerned in the decision-making for medical care of prostate cancer patients in favor of reserved care strategies.

Identifiants

pubmed: 31047783
pii: S1078-1439(19)30140-1
doi: 10.1016/j.urolonc.2019.04.007
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

575.e1-575.e7

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Peter Klippenstein (P)

Martini-Klinik, Prostate Cancer Center, Medical University Hamburg Eppendorf, Hamburg, Germany.

Thorsten Schlomm (T)

Martini-Klinik, Prostate Cancer Center, Medical University Hamburg Eppendorf, Hamburg, Germany.

Gunhild von Amsberg (G)

Clinic of Oncology, Haematology and Bone Marrow Transplant, Medical University Hamburg Eppendorf, Hamburg, Germany.

Burkhard Beyer (B)

Martini-Klinik, Prostate Cancer Center, Medical University Hamburg Eppendorf, Hamburg, Germany.

Raisa S Pompe (RS)

Martini-Klinik, Prostate Cancer Center, Medical University Hamburg Eppendorf, Hamburg, Germany.

Uwe Michl (U)

Martini-Klinik, Prostate Cancer Center, Medical University Hamburg Eppendorf, Hamburg, Germany.

Georg Salomon (G)

Martini-Klinik, Prostate Cancer Center, Medical University Hamburg Eppendorf, Hamburg, Germany.

Imke Thederan (I)

Martini-Klinik, Prostate Cancer Center, Medical University Hamburg Eppendorf, Hamburg, Germany.

Lars Budäus (L)

Martini-Klinik, Prostate Cancer Center, Medical University Hamburg Eppendorf, Hamburg, Germany.

Hans Heinzer (H)

Martini-Klinik, Prostate Cancer Center, Medical University Hamburg Eppendorf, Hamburg, Germany.

Derya Tilki (D)

Martini-Klinik, Prostate Cancer Center, Medical University Hamburg Eppendorf, Hamburg, Germany.

Alexander Haese (A)

Martini-Klinik, Prostate Cancer Center, Medical University Hamburg Eppendorf, Hamburg, Germany.

Hartwig Huland (H)

Martini-Klinik, Prostate Cancer Center, Medical University Hamburg Eppendorf, Hamburg, Germany.

Markus Graefen (M)

Martini-Klinik, Prostate Cancer Center, Medical University Hamburg Eppendorf, Hamburg, Germany.

Thomas Steuber (T)

Martini-Klinik, Prostate Cancer Center, Medical University Hamburg Eppendorf, Hamburg, Germany.

Pierre Tennstedt (P)

Martini-Klinik, Prostate Cancer Center, Medical University Hamburg Eppendorf, Hamburg, Germany. Electronic address: p.tennstedt@uke.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH